Establishment of a Biobank for the Evaluation of Rapid Diagnostic Solutions
Establishment of a Biobank for the Evaluation of Rapid Diagnostic Solutions for Emerging Infectious Diseases and CBRN Threats - DiagRaMIE Biobanque
Assistance Publique - Hôpitaux de Paris
800 participants
Jun 3, 2024
OBSERVATIONAL
Conditions
Summary
This multicenter prospective registry aims to establish a biobank of residual biological samples and associated clinical data from hospitalized patients. The registry will collect a wide range of specimens (serum, plasma, respiratory samples, urine, cerebrospinal fluid, biopsies) obtained during routine care, without any additional procedures. Data are pseudonymized and stored securely for up to 20 years. The biobank will be used to develop and evaluate rapid diagnostic tests (RDTs) for emerging infectious diseases and CBRN threats to improve epidemic preparedness and patient management.
Eligibility
Inclusion Criteria3
- Adults (≥ 18 years old) hospitalized in one of the participating centers at Bicêtre or Paul Brousse hospitals, for whom residual biological samples are available as part of routine care in one or more participating hospital departments.
- Covered by, or entitled to, the French social security system (excluding State Medical Aid - AME).
- Patient or legal representative/trusted person informed about the registry and having provided written consent to participate.
Exclusion Criteria3
- Patients under judicial protection (guardianship or curatorship).
- Patients deprived of liberty by judicial or administrative decision.
- Patients not speaking French and not accompanied by a translator.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(10)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07411729